Welcome to our dedicated page for Quipt Home Medical SEC filings (Ticker: QIPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quipt Home Medical Corp. (QIPT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, with AI-powered tools to help interpret complex documents. Quipt is a British Columbia corporation whose common shares trade on The Nasdaq Capital Market and the Toronto Stock Exchange, and it files reports with the U.S. Securities and Exchange Commission in connection with its status as a reporting issuer.
Among the key filings for Quipt are its Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, management’s discussion and analysis, and details on its home medical equipment and in-home respiratory care business in the United States healthcare market. These filings expand on topics referenced in press releases, such as recurring revenue from equipment rentals and respiratory resupplies, non-GAAP measures like Adjusted EBITDA, and risk factors related to reimbursement, regulation, and acquisitions.
Quipt also files Form 8-K current reports to disclose material events. Recent examples include an August 11, 2025 Form 8-K furnishing a press release on fiscal third quarter 2025 results, an August 12, 2025 Form 8-K describing the Equity Purchase Agreement for a 60% interest in Hart Medical Equipment, and a July 7, 2025 Form 8-K discussing the acquisition of a Ballad Health-owned durable medical equipment provider. On December 15, 2025, Quipt filed a Form 8-K detailing its entry into an Arrangement Agreement under which entities affiliated with Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for US$3.65 per share in cash.
These filings explain that, if the arrangement is consummated, Quipt’s shares will be delisted from The Nasdaq Capital Market and the Toronto Stock Exchange, de-registered under the Securities Exchange Act of 1934, and Quipt will cease to be a reporting issuer under Canadian securities laws. Until that transaction closes, investors can use this page to review Quipt’s ongoing SEC disclosures, including 8-Ks related to financial results, acquisitions, joint ventures, and the planned going-private transaction.
Stock Titan’s interface surfaces real-time updates from EDGAR and applies AI-generated summaries to help users quickly understand the contents of lengthy filings, including the implications of transaction agreements, non-GAAP reconciliations, and other technical disclosures related to Quipt’s home medical equipment and respiratory care operations.
Quipt Home Medical Corp. has completed its previously announced sale to two buyers, 1567208 B.C. Ltd. and REM Aggregator, LLC. All outstanding common shares were acquired for cash consideration of $3.65 per share, without interest. As a result of this transaction, the reporting investors Forager Fund, L.P., Forager Capital Management, LLC, Edward Kissel, and Robert MacArthur report that they no longer beneficially own any Quipt common shares and now show 0 shares and 0% of the class.
Quipt Home Medical director Brian Joseph Wessel reported dispositions of his equity in connection with the company’s acquisition. On March 16, 2026, all of his 75,000 stock options with a $4.99 exercise price and 116,854 common shares held directly were disposed of to the issuer under a plan of arrangement that paid $3.65 per share in cash for each common share. An additional 98,875 common shares were disposed of from the B & E Wessel Family Trust, which holds the shares for the benefit of Brian and Eliana Wessel and their children; Mr. Wessel disclaims beneficial ownership of these trust-held securities. Footnotes state that, at the effective time of the arrangement, all issued and outstanding common shares were transferred to the purchasers for cash and all vested options were surrendered for a cash payment equal to the excess, if any, of $3.65 over the option exercise price, while options with exercise prices at or above $3.65 and 80,406 restricted share units were cancelled without consideration.
Quipt Home Medical Corp. Chief Accounting Officer Thomas Roehrig reported disposing of all his reported equity interests in connection with the company’s cash acquisition. He returned stock options covering 50,000, 50,000 and 30,000 common shares with exercise prices of $2.45, $6.27 and $6.14 per share to the issuer. He also disposed of 173,000 common shares at $3.65 per share to the purchaser under a plan of arrangement that cashed out all outstanding common shares at $3.65 per share. Following these transactions, the filing shows no remaining shares or options held.
Quipt Home Medical Corp. Chief Compliance Officer Miles Mark Alan reported dispositions of both common shares and stock options tied to the company’s go‑private transaction. On March 16, 2026, he disposed of 110,000 common shares at US$3.65 per share to the acquiring purchasers under a plan of arrangement.
He also disposed of 57,500 stock options, with exercise prices of US$1.11, US$6.27, and US$6.14, which were treated in cash in line with the arrangement terms. Following these transactions, the filing shows he holds no remaining Quipt common shares or stock options.
Quipt Home Medical Corp. director Mark Alan Greenberg reported disposing of his equity position in connection with the company’s plan of arrangement. On March 16, 2026, he transferred 435,457 common shares at $3.65 per share to the purchaser and surrendered stock options for 488,750 common shares back to the issuer. Under the arrangement terms, all Quipt common shares were acquired for $3.65 in cash, certain restricted share units totaling 92,862 were forfeited, and options with exercise prices at or above $3.65 were cancelled without consideration.
Quipt Home Medical Corp. executive Patrick Dennis Gamble has fully exited his equity position as part of the company’s cash acquisition. On March 16, 2026, he disposed of 60,057 Common Shares at US$3.65 per share in a disposition to the issuer under a plan of arrangement.
He also surrendered 15,000 stock options with a US$6.14 exercise price, which were cancelled for no consideration because the exercise price was at or above the US$3.65 cash deal value. Following these transactions, the filing shows he holds no remaining shares or options.
Quipt Home Medical Corp.’s President and CEO Gregory John Crawford reported that all of his equity in the company was cashed out in connection with a change-of-control transaction. Under a court-approved plan of arrangement, all common shares were transferred to purchasers for US$3.65 per share in cash.
Crawford disposed of 3,351,196 common shares held directly at US$3.65 per share, plus additional shares held indirectly by his spouse and by the Gregory J. Crawford Family 2017 Children's Trust, for which he disclaims beneficial ownership. A stock option covering 75,000 shares with a US$6.27 exercise price was also surrendered to the issuer under the arrangement’s option treatment provisions. Following these transactions, the filing shows no remaining shares or options held.
Quipt Home Medical Corp. director Kevin A. Carter disposed of his remaining equity position in connection with the company’s acquisition. On March 16, 2026, all 201,160 of his Common Shares were transferred under a plan of arrangement for a cash payment of US$3.65 per share. In addition, 5,625 stock options with a US$6.27 exercise price were surrendered to the issuer and cancelled with no cash consideration, consistent with the arrangement terms that options priced at or above US$3.65 receive no payment. Following these transactions, Carter no longer holds Quipt common shares or related options.
Quipt Home Medical Corp. executive vice president of operations David Bachelder reported disposing of his equity positions in connection with the company’s cash acquisition. He surrendered 80,000 stock options, with exercise prices of US$4.99 and US$6.14, back to the issuer and disposed of 22,156 common shares at US$3.65 per share, all coded as dispositions to the issuer.
Under the arrangement, all Quipt common shares were transferred to the purchasers for US$3.65 in cash, while restricted share units were cashed out at the same price less taxes. Options became fully vested and were surrendered for any intrinsic value above US$3.65, with underwater options canceled for no consideration. Following these transactions, Bachelder no longer reports any remaining shares or options.